Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$325.72M$325.72M+40.8% vs Q2 2024 Net Income$165.16M$165.16M+77.1% vs Q2 2024 EPS Diluted$1.33$1.33+84.7% vs Q2 2024 Operating Income$202,441,000+72.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$98,148,000+84.4% Margins · derivedOperating margin62.2%+11.5 pt vs Q2 2024
Net margin50.7%+10.4 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 5, 2025 · 36 d after period end